CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 9 No. 6
 

Intergroup Melanoma Surgical Trial Validates 2-cm Excision

June 1, 2000

NEW ORLEANS—Long-term follow-up of patients who underwent surgical excision of intermediate-thickness melanomas offers valuable information regarding the risk of local recurrence, especially as it relates to treatment.

Charles M. Balch, MD, professor of surgery, Johns Hopkins University, presented the findings at a plenary session of the Society of Surgical Oncology (SSO) Cancer Symposium, on behalf of the Intergroup Melanoma Surgical Trial.

The results were based on 15-year follow-up of 740 patients: 468 patients with 1- to 4-mm melanomas on the trunk or proximal extremities (group A), and 272 patients with lesions on the head, neck, and distal extremities (group B).

Patients in group A were randomized to receive either 2- or 4-cm radial excision margins, while group B patients received 2-cm excisions. Patients were also randomized either to elective lymph node dissection or observation of the nodes.

At the time of the study, the standard of care was to excise all melanomas larger than 1 mm with a 4- to 5-cm margin and a split-thickness skin graft. This study aimed to determine if the margins of excision could be reduced safely; the researchers focused on the incidence of local recurrence, which is significantly related to survival.

Local recurrence (at any time during the course of the disease) was noted in 28 patients: 11 patients (2.3%) from group A and 17 (6.3%) from group B. In 13 patients, local recurrence was the first sign of relapse; most were in group B, probably because of their disease location, Dr. Balch said. “There is a statistical correlation between local recurrence and anatomic site, ranging from 1.1% in the proximal extremities to 9.4% for head and neck melanomas,” he elaborated.

A local recurrence at any time during progression of metastatic disease carried a 5-year survival rate of only 11% and a 10-year survival of 0%. For patients without a local recurrence, the 10-year survival rate was 86% (P < .0001), Dr. Balch reported.

Factors Affecting Local Recurrence

The extent of margin excision did not make a difference in the risk of local recurrence: 2.1% for the patients receiving a 2-cm excision and 2.6% for those undergoing a 4-cm excision. Management of regional lymph nodes—dissection vs observation—also was not a factor in local recurrence, he noted.

Survival also was not affected by margin excision: 10-year survival was 70% after a 2-cm excision and 77% after a

4-cm excision (a nonsignificant difference). Management of nodes also did not influence survival.

Several factors were, however, significantly related to the incidence of local recurrence, with P values of .01 or less, Dr. Balch noted. Increasing tumor thickness among the patients in group B was strongly correlated with local recurrence of disease, especially for lesions 3.1 to 4.0 cm in size.

Another powerful correlate was the presence of ulceration in the primary melanoma in both groups A and B. In group B, ulceration produced an eightfold increase in risk of local recurrence, rising from 2.1% without ulceration to 16.2% when ulceration was present. In group A, risk increased fivefold, from 1.1% to 6.6%, he reported.

By Cox multifactorial regression analysis, the only factor independently correlating with the rate of local recurrence was the presence or absence of ulceration (risk ratio, 4.2; P = .03).

No independent correlation was found for margins of excision, tumor thickness, site, or elective dissection of nodes, in this analysis.

When groups A and B were pooled for analysis, the only additional factor correlating with the incidence of local recurrence was the presence of melanoma on the head or neck, which yielded a 9.4 risk ratio (P < .01).

An important question was whether a wider margin would prevent local recurrence, especially in thicker or ulcerated lesions. While this makes intuitive sense, it was not demonstrated in this study, Dr. Balch stated.

“Based on thickness parameters or ulceration, we can’t say that wider excision decreases the risk of recurrence,” he commented.

The study also examined relapse patterns to determine whether the local recurrences represented retained primary tumor cells or were the first manifestation of distant or stage IV melanoma. In 68% of patients, the next site of relapse occurred at a distant site, usually in the skin or subcutaneous lymph nodes.

The trial results, Dr. Balch concluded, showed that:

  • A 2-cm radial excision is safe and reduces the need for split-thickness skin graft.

  • Ulceration and melanomas arising in the head and neck increase the risk of local recurrence as well as mortality.

  • A local recurrence is associated with a very high risk of subsequent metastases at distant sites.

  • A local recurrence is probably the first manifestation of stage IV melanoma.

WHO Results With 1-cm Margins

Intergroup coinvestigator Kirby Bland, MD, professor and chairman of surgery, University of Alabama at Birmingham, called the ongoing analysis a “very strong contribution to the literature.” He noted that Intergroup Melanoma Trial 10 of the World Health Organization (WHO) found that it was safe to excise melanomas up to 2 mm in thickness with a 1-cm margin, and asked Dr. Balch to comment.

Dr. Balch responded that with a 1-cm excision, the WHO trial’s local recurrence rate for T2 lesions was 6%, compared with less than 1% for lesions of equivalent thickness in the US Intergroup study.

He added that in some patients, he would consider reducing the margin to 1 to 2 cm to avoid the need for primary closure and achieve a better cosmetic result.


 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy